Heparin-protein interactions.

Heparin, a sulfated polysaccharide belonging to the family of glycosaminoglycans, has numerous important biological activities, associated with its interaction with diverse proteins. Heparin is widely used as an anticoagulant drug based on its ability to accelerate the rate at which antithrombin inhibits serine proteases in the blood coagulation cascade. Heparin and the structurally related heparan sulfate are complex linear polymers comprised of a mixture of chains of different length, having variable sequences. Heparan sulfate is ubiquitously distributed on the surfaces of animal cells and in the extracellular matrix. It also mediates various physiologic and pathophysiologic processes. Difficulties in evaluating the role of heparin and heparan sulfate in vivo may be partly ascribed to ignorance of the detailed structure and sequence of these polysaccharides. In addition, the understanding of carbohydrate-protein interactions has lagged behind that of the more thoroughly studied protein-protein and protein-nucleic acid interactions. The recent extensive studies on the structural, kinetic, and thermodynamic aspects of the protein binding of heparin and heparan sulfate have led to an improved understanding of heparin-protein interactions. A high degree of specificity could be identified in many of these interactions. An understanding of these interactions at the molecular level is of fundamental importance in the design of new highly specific therapeutic agents. This review focuses on aspects of heparin structure and conformation, which are important for its interactions with proteins. It also describes the interaction of heparin and heparan sulfate with selected families of heparin-binding proteins.

[1]  A. Luster,et al.  Chemokines--chemotactic cytokines that mediate inflammation. , 1998, The New England journal of medicine.

[2]  J. Putten,et al.  Vitronectin binds to the gonococcal adhesin OpaA through a glycosaminoglycan molecular bridge. , 1998, The Biochemical journal.

[3]  J. Holbrook,et al.  The interaction of platelet factor 4 with heparins of different chain length. , 1984, Biochimica et biophysica acta.

[4]  N. Heegaard,et al.  A heparin‐binding peptide from human serum amyloid P component characterized by affinity capillary electrophoresis , 1998, Electrophoresis.

[5]  B. Seaton,et al.  Interaction of heparin with annexin V , 1999, FEBS letters.

[6]  A. R. Todd,et al.  Observations on the structure of the barium salt of heparin. , 1940, The Biochemical journal.

[7]  R. Rosenberg,et al.  The purification and mechanism of action of human antithrombin-heparin cofactor. , 1973, The Journal of biological chemistry.

[8]  T. Springer,et al.  A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1) , 1996, The Journal of experimental medicine.

[9]  A. Lander,et al.  Differential binding of chemokines to glycosaminoglycan subpopulations , 1994, Current Biology.

[10]  J. Feeney,et al.  Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro. , 1994, Biochemistry.

[11]  M. Auer,et al.  Transcytosis and Surface Presentation of IL-8 by Venular Endothelial Cells , 1997, Cell.

[12]  K. Mayo,et al.  Heparin Dodecasaccharide Binding to Platelet Factor-4 and Growth-related Protein-α , 1999, The Journal of Biological Chemistry.

[13]  R. Linhardt,et al.  Conformational study of synthetic delta 4-uronate monosaccharides and glycosaminoglycan-derived disaccharides. , 1998, Carbohydrate research.

[14]  C. V. van Noorden,et al.  The complex effects of heparins on cancer progression and metastasis in experimental studies. , 2001, Pharmacological reviews.

[15]  R. Langer,et al.  Heparinase III from Flavobacterium heparinum: cloning and recombinant expression in Escherichia coli. , 1996, Biochemical and biophysical research communications.

[16]  Cornelis Altona,et al.  Force field parameters for sulfates and sulfamates based on ab initio calculations: Extensions of AMBER and CHARMm fields , 1995, J. Comput. Chem..

[17]  R. Hubbard,et al.  Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. , 1999, Biochemistry.

[18]  H. Kitagawa,et al.  Characterization of recombinant human glucuronyltransferase I involved in the biosynthesis of the glycosaminoglycan‐protein linkage region of proteoglycans , 1999, FEBS letters.

[19]  R. Linhardt,et al.  Interaction of Secretory Leukocyte Protease Inhibitor with Heparin Inhibits Proteases Involved in Asthma* , 1998, The Journal of Biological Chemistry.

[20]  M. Petitou,et al.  Interaction of heparin and antithrombin III. The role of O-sulfate groups. , 1988, European journal of biochemistry.

[21]  R. Sasisekharan,et al.  Heparinase I from Flavobacterium heparinum , 1998, The Journal of Biological Chemistry.

[22]  Rebecca C. Wade,et al.  Docking of Glycosaminoglycans to Heparin-Binding Proteins: Validation for aFGF, bFGF, and Antithrombin and Application to IL-8 , 1999 .

[23]  C L Cooney,et al.  Heparinase inhibits neovascularization. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Cardin,et al.  Molecular Modeling of Protein‐Glycosaminoglycan Interactions , 1989, Arteriosclerosis.

[25]  B. Edwards,et al.  A model of the platelet factor 4 complex with heparin , 1992, Proteins.

[26]  R. Linhardt,et al.  Regio and stereoselective conversion of Δ4-uronic acids to l-Ido- and d-glucopyranosiduronic acids , 1997 .

[27]  A. Zlotnik,et al.  The biology of chemokines and their receptors. , 2000, Annual review of immunology.

[28]  M. Nybo,et al.  Calcium-dependent and -independent binding of the pentraxin serum amyloid P component to glycosaminoglycans and amyloid proteins: enhanced binding at slightly acid pH. , 1997, Biochimica et biophysica acta.

[29]  Steven M. Wolinsky,et al.  The role of a mutant CCR5 allele in HIV–1 transmission and disease progression , 1996, Nature Medicine.

[30]  Pablo Engel,et al.  The selecting: vascular adhesion molecules , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  J. Weiler,et al.  Importance of specific amino acids in protein binding sites for heparin and heparan sulfate. , 1996, The international journal of biochemistry & cell biology.

[32]  Maurice Petitou,et al.  Die ersten synthetischen Kohlenhydrate mit den vollständigen antikoagulierenden Eigenschaften von Heparin , 1998 .

[33]  A. Levinson,et al.  The Transforming Growth Factor‐Betas: A New Family of Immunoregulatory Molecules , 1990, Annals of the New York Academy of Sciences.

[34]  R. Linhardt,et al.  Purification and characterization of a novel heparinase from Bacteroides stercoris HJ-15. , 2000, Journal of biochemistry.

[35]  R. Linhardt,et al.  Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site. , 2000, Thrombosis research.

[36]  U. Lindahl,et al.  Biosynthesis of heparin. The D-glucuronosyl- and N-acetyl-D-glucosaminyltransferase reactions and their relation to polymer modification. , 1992, The Biochemical journal.

[37]  K. Biemann,et al.  Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Linhardt,et al.  Isolation and characterization of heparan sulfate from crude porcine intestinal mucosal peptidoglycan heparin. , 1995, Carbohydrate research.

[39]  E. Appella,et al.  Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[40]  B. Herold,et al.  Heparan sulfate glycosaminoglycans as primary cell surface receptors for herpes simplex virus. , 1992, Advances in experimental medicine and biology.

[41]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[42]  H. Rauvala An 18‐kd heparin‐binding protein of developing brain that is distinct from fibroblast growth factors. , 1989, The EMBO journal.

[43]  B. Rupp,et al.  Interaction of the N-terminal domain of apolipoprotein E4 with heparin. , 2001, Biochemistry.

[44]  H. Hamazaki Ca2+-mediated association of human serum amyloid P component with heparan sulfate and dermatan sulfate. , 1987, The Journal of biological chemistry.

[45]  C. W. von der Lieth,et al.  Efficient modelling protocols for oligosaccharides: from vacuum to solvent , 1997, Glycoconjugate Journal.

[46]  S. Moss,et al.  Annexins and membrane dynamics. , 1997, Biochimica et biophysica acta.

[47]  Luigi Buonaguro,et al.  HIV‐1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix‐associated heparan sulfate proteoglycans through its basic region , 1997, AIDS.

[48]  Anne Imberty,et al.  Characterization of the Stromal Cell-derived Factor-1α-Heparin Complex* , 2001, The Journal of Biological Chemistry.

[49]  J. Weiler,et al.  Differences in the interaction of heparin with arginine and lysine and the importance of these basic amino acids in the binding of heparin to acidic fibroblast growth factor. , 1995, Archives of biochemistry and biophysics.

[50]  D. Rees,et al.  Diversity does make a difference: fibroblast growth factor-heparin interactions. , 1998, Current opinion in structural biology.

[51]  M. Charng,et al.  FKBP-12 Recognition Is Dispensable For Signal Generation by Type I Transforming Growth Factor-β Receptors* , 1996, The Journal of Biological Chemistry.

[52]  J. Dawes Measurement of the affinities of heparins, naturally occurring glycosaminoglycans, and other sulfated polymers for antithrombin III and thrombin. , 1988, Analytical biochemistry.

[53]  B. Faller,et al.  Heparin-induced conformational change and activation of mucus proteinase inhibitor. , 1992, Biochemistry.

[54]  J. Esko,et al.  An Animal Cell Mutant Defective in Heparan Sulfate Hexuronic Acid 2-O-Sulfation* , 1996, The Journal of Biological Chemistry.

[55]  J. Turnbull,et al.  Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor. , 1994, The Journal of biological chemistry.

[56]  T. Shimomura,et al.  Heparin modulates the receptor-binding and mitogenic activity of hepatocyte growth factor on hepatocytes. , 1993, Experimental cell research.

[57]  J. Sparrow,et al.  Binding of a high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains. , 1986, Biochemical and biophysical research communications.

[58]  T. Krusat,et al.  Heparin-dependent attachment ofrespiratory syncytial virus (RSV) to host cells , 1997, Archives of Virology.

[59]  J. Holbrook,et al.  Low-resolution structure of the complex of human blood platelet factor 4 with heparin determined by small-angle neutron scattering. , 1986, Biochimica et biophysica acta.

[60]  A. Varki,et al.  Calcium-dependent heparin-like ligands for L-selectin in nonlymphoid endothelial cells. , 1993, Science.

[61]  K. Yoshida,et al.  Human Homolog of Caenorhabditis elegans sqv-3 Gene Is Galactosyltransferase I Involved in the Biosynthesis of the Glycosaminoglycan-Protein Linkage Region of Proteoglycans* , 1999, The Journal of Biological Chemistry.

[62]  R. Linhardt,et al.  Nature of the interaction of heparin with acidic fibroblast growth factor. , 1993, Biochemistry.

[63]  L. Naldini,et al.  Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth , 1992, The Journal of cell biology.

[64]  H. Messmore,et al.  State-of-the-Art Review : Heparin-induced Thrombocytopenia and Thrombosis Syndrome , 1998 .

[65]  U. Desai,et al.  Role of Arginine 129 in Heparin Binding and Activation of Antithrombin* , 2000, The Journal of Biological Chemistry.

[66]  B. Herold,et al.  Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulphate and glycoprotein B. , 1994, The Journal of general virology.

[67]  A. Lander,et al.  Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: development of a sensitive electrophoretic approach. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[68]  R. Linhardt,et al.  Thermodynamic analysis of the heparin interaction with a basic cyclic peptide using isothermal titration calorimetry. , 1998, Biochemistry.

[69]  T. Muramatsu,et al.  Expression of a carbohydrate signal, sialyl dimeric Le(x) antigen, is associated with metastatic potential of transitional cell carcinoma of the human urinary bladder. , 1991, Biochemical and biophysical research communications.

[70]  C. Parish,et al.  A rapid quantitative assay for the detection of mammalian heparanase activity. , 1997, The Biochemical journal.

[71]  D. Ornitz,et al.  FGFs, heparan sulfate and FGFRs: complex interactions essential for development. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[72]  P. Fraser,et al.  Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease , 1995, Nature Medicine.

[73]  Z. Shriver,et al.  Heparinase II from Flavobacterium heparinum , 1998, The Journal of Biological Chemistry.

[74]  D. Hoppensteadt,et al.  An update on heparins at the beginning of the new millennium. , 2000, Seminars in thrombosis and hemostasis.

[75]  R. Samulski,et al.  Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions , 1998, Journal of Virology.

[76]  Simi Ali,et al.  Examination of the Function of RANTES, MIP-1α, and MIP-1β following Interaction with Heparin-like Glycosaminoglycans* , 2000, The Journal of Biological Chemistry.

[77]  U. Lindahl,et al.  Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[78]  W. Sicinska,et al.  A detailed 1H and 13C NMR study of a repeating disaccharide of hyaluronan: the effects of temperature and counterion type. , 1993, Carbohydrate research.

[79]  A. Varki,et al.  Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. , 1998, The Journal of clinical investigation.

[80]  H. Rubin Serine protease inhibitors (SERPINS): Where mechanism meets medicine , 1996, Nature Medicine.

[81]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[82]  X. Wu,et al.  Requirement for Anticoagulant Heparan Sulfate in the Fibroblast Growth Factor Receptor Complex* , 1999, The Journal of Biological Chemistry.

[83]  S. Stringer,et al.  Specific Binding of the Chemokine Platelet Factor 4 to Heparan Sulfate* , 1997, The Journal of Biological Chemistry.

[84]  M Sobel,et al.  Structure-function relations of antithrombin III-heparin interactions as assessed by biophysical and biological assays and molecular modeling of peptide-pentasaccharide-docked complexes. , 1996, Archives of biochemistry and biophysics.

[85]  H. Nader,et al.  Conformation of the Unsaturated Uronic Acid Residues of Glycosamtnoglycan Disaccharides , 1993 .

[86]  C. McCormick,et al.  The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[87]  I. Danishefsky,et al.  Preparation of highly stable antithrombin-sepharose and utilization for the fractionation of heparin. , 1982, Thrombosis research.

[88]  A. Malmström,et al.  Biosynthesis of L-iduronic acid in heparin: epimerization of D-glucuronic acid on the polymer level. , 1972, Biochemical and biophysical research communications.

[89]  A. Aruffo,et al.  Granule membrane protein 140 (GMP140) binds to carcinomas and carcinoma-derived cell lines. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[90]  R. Carrell,et al.  Heparin binding site, conformational change, and activation of antithrombin. , 1992, Biochemistry.

[91]  D. Hoover,et al.  The Crystal Structure of the Chemokine Domain of Fractalkine Shows a Novel Quaternary Arrangement* , 2000, The Journal of Biological Chemistry.

[92]  M. Forster,et al.  N.m.r. and molecular-modelling studies of the solution conformation of heparin. , 1993, The Biochemical journal.

[93]  H. Kitagawa,et al.  Molecular Cloning and Expression of Glucuronyltransferase I Involved in the Biosynthesis of the Glycosaminoglycan-Protein Linkage Region of Proteoglycans* , 1998, The Journal of Biological Chemistry.

[94]  I. Danishefsky,et al.  Evidence for a heparin-induced conformational change on antithrombin III. , 1977, Biochemical and biophysical research communications.

[95]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[96]  E. Henningsson,et al.  Crossed immunoelectrophoresis as applied to studies on complex formation. The binding of heparin to antithrombin III and the antithrombin III--thrombin complex. , 1977, Journal of immunological methods.

[97]  J. Weiler,et al.  Two-dimensional affinity resolution electrophoresis demonstrates that three distinct heparin populations interact with antithrombin III. , 1995, Biochemistry.

[98]  K. Biemann,et al.  Mass spectrometric evidence for the enzymatic mechanism of the depolymerization of heparin-like glycosaminoglycans by heparinase II. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[99]  F. Robey,et al.  The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. , 1992, The Journal of biological chemistry.

[100]  R. Kisilevsky,et al.  Sulfated glycosaminoglycans: a common constituent of all amyloids? , 1987, Laboratory investigation; a journal of technical methods and pathology.

[101]  Joseph Sodroski,et al.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.

[102]  U. R. Desai,et al.  Specificity studies on the heparin lyases from Flavobacterium heparinum. , 1993, Biochemistry.

[103]  J. Rand,et al.  Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism. , 1997, The New England journal of medicine.

[104]  P. Fisher,et al.  Expression of Human Papilloma Virus E7 Protein Causes Apoptosis and Inhibits DNA Synthesis in Primary Hepatocytes via Increased Expression of p21Cip-1/WAF1/MDA6 * , 2000, The Journal of Biological Chemistry.

[105]  T. McCutchan,et al.  Heparin can regulate the binding of Plasmodium falciparum circumsporozoite protein. , 2000, Molecular and biochemical parasitology.

[106]  M. Konishi,et al.  Identification of a novel FGF, FGF-21, preferentially expressed in the liver. , 2000, Biochimica et biophysica acta.

[107]  P. Wingfield,et al.  Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation , 1993, Journal of virology.

[108]  V. Nussenzweig,et al.  The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of plasmodium falciparum sporozoites , 1992, Cell.

[109]  J. Fareed,et al.  STRUCTURAL STUDIES ON A BIOLOGICALLY ACTIVE HEXASACCHARIDE OBTAINED FROM HEPARIN , 1981, Annals of the New York Academy of Sciences.

[110]  Bernhard Moser,et al.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 , 1996, Nature.

[111]  D. Waisman,et al.  Characterization of the Heparin Binding Properties of Annexin II Tetramer* , 1997, The Journal of Biological Chemistry.

[112]  R. Langer,et al.  Cloning and expression of heparinase I gene from Flavobacterium heparinum. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[113]  M. Delepierre,et al.  Stromal Cell-derived Factor-1α Associates with Heparan Sulfates through the First β-Strand of the Chemokine* , 1999, The Journal of Biological Chemistry.

[114]  J. Herbert,et al.  First Synthetic Carbohydrates with the Full Anticoagulant Properties of Heparin. , 1998, Angewandte Chemie.

[115]  S. V. van Duinen,et al.  Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[116]  E. Jorpes,et al.  Der Aminozucker des Heparins. , 1936 .

[117]  J. Spring,et al.  Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. , 1992, Annual review of cell biology.

[118]  H. Su,et al.  Isolation and expression in Escherichia coli of hepB and hepC, genes coding for the glycosaminoglycan-degrading enzymes heparinase II and heparinase III, respectively, from Flavobacterium heparinum , 1996, Applied and environmental microbiology.

[119]  D. Spillmann,et al.  Characterization of Heparin and Heparan Sulfate Domains Binding to the Long Splice Variant of Platelet-derived Growth Factor A Chain* , 1997, The Journal of Biological Chemistry.

[120]  J. Abraham,et al.  Characterization of sequences within heparin-binding EGF-like growth factor that mediate interaction with heparin. , 1994, The Journal of biological chemistry.

[121]  A. Drake,et al.  The effect of variation of substitution on the solution conformation of heparin: a spectroscopic and molecular modelling study. , 1994, Carbohydrate research.

[122]  B. Seaton,et al.  Annexin V--heparin oligosaccharide complex suggests heparan sulfate--mediated assembly on cell surfaces. , 2001, Structure.

[123]  David R. Nadeau,et al.  Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[124]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[125]  G. Waksman,et al.  FGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharides. , 1995, Science.

[126]  B. Svennerholm,et al.  Herpes Simplex Virus Types 1 and 2 Differ in Their Interaction with Heparan Sulfate , 2000, Journal of Virology.

[127]  R. Langer,et al.  Heparinase I from Flavobacterium heparinum. Identification of a critical histidine residue essential for catalysis as probed by chemical modification and site-directed mutagenesis. , 1996, Biochemistry.

[128]  J. Walenga,et al.  Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. , 1998, The Medical clinics of North America.

[129]  R. Yolken,et al.  Human milk glycosaminoglycans inhibit HIV glycoprotein gp120 binding to its host cell CD4 receptor. , 1995, The Journal of nutrition.

[130]  U. Desai,et al.  Mechanism of Heparin Activation of Antithrombin , 1998, The Journal of Biological Chemistry.

[131]  Q. Sattentau,et al.  The CD4 antigen: Physiological ligand and HIV receptor , 1988, Cell.

[132]  P. Sanderson,et al.  Conformational equilibria of alpha-L-iduronate residues in disaccharides derived from heparin. , 1987, The Biochemical journal.

[133]  B. Casu,et al.  Structure and biological activity of heparin. , 1985, Advances in carbohydrate chemistry and biochemistry.

[134]  R. Linhardt,et al.  Preparation and structure of heparin lyase-derived heparan sulfate oligosaccharides. , 1997, Glycobiology.

[135]  K. Yoshida,et al.  Importance of 2-O-sulfate groups of uronate residues in heparin for activation of FGF-1 and FGF-2. , 1995, Journal of biochemistry.

[136]  M. Kaksonen,et al.  Heparin-binding Growth-associated Molecule Contains Two Heparin-binding β-Sheet Domains That Are Homologous to the Thrombospondin Type I Repeat* , 2000, The Journal of Biological Chemistry.

[137]  D. Feingold,et al.  A vintage year for Jorpes, Crafoord, and heparin , 1985 .

[138]  T. Peters,et al.  Conformational analysis of synthetic heparin-like oligosaccharides containing α-L-idopyranosyluronic acid† , 1987 .

[139]  M. Baggiolini,et al.  Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[140]  J. Schlessinger,et al.  Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. , 2000, Molecular cell.

[141]  D C Rees,et al.  Heparin Structure and Interactions with Basic Fibroblast Growth Factor , 1996, Science.

[142]  B. Moss,et al.  Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[143]  J. Weiler,et al.  Heparin and modified heparin inhibit complement activation in vivo. , 1992, Journal of immunology.

[144]  J. Thompson,et al.  Heparin-dependent fibroblast growth factor activities: effects of defined heparin oligosaccharides. , 1997, European Journal of Cell Biology.

[145]  Z. Shriver,et al.  Histidine 295 and histidine 510 are crucial for the enzymatic degradation of heparan sulfate by heparinase III. , 2000, Biochemistry.

[146]  J. Goudsmit,et al.  Neutralization of HIV‐1: a paradox of humoral proportions , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[147]  J. Luban,et al.  Specific incorporation of cyclophilin A into HIV-1 virions , 1994, Nature.

[148]  R. Linhardt,et al.  Interaction of soluble and surface‐bound heparin binding growth‐associated molecule with heparin , 1999, FEBS letters.

[149]  N. Cooper,et al.  Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. , 1993, Virology.

[150]  B. Herold,et al.  Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry , 1996, Journal of virology.

[151]  J. Pelt,et al.  Organ and species specificity of hepatitis B virus (HBV) infection: a review of literature with a special reference to preferential attachment of HBV to human hepatocytes , 1997, Journal of viral hepatitis.

[152]  J. Xu,et al.  An essential heparin-binding domain in the fibroblast growth factor receptor kinase. , 1993, Science.

[153]  O. Ratnoff,et al.  SOME PROPERTIES OF AN ESTERASE DERIVED FROM PREPARATIONS OF THE FIRST COMPONENT OF COMPLEMENT , 1957, The Journal of experimental medicine.

[154]  K. Rice,et al.  Interterminal distance and flexibility of a triantennary glycopeptide as measured by resonance energy transfer. , 1991, Biochemistry.

[155]  David F. Burke,et al.  Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin , 2000, Nature.

[156]  J. Weiler,et al.  Heparin binding and augmentation of C1 inhibitor activity. , 1999, Archives of biochemistry and biophysics.

[157]  R. Langer,et al.  An enzymatic system for removing heparin in extracorporeal therapy. , 1982, Science.

[158]  Q. Sattentau,et al.  Human Immunodeficiency Virus Type 1 Attachment to HeLa CD4 Cells Is CD4 Independent and gp120 Dependent and Requires Cell Surface Heparans , 1998, Journal of Virology.

[159]  V. Nussenzweig,et al.  Remnant lipoproteins inhibit malaria sporozoite invasion of hepatocytes , 1996, The Journal of experimental medicine.

[160]  J. V. van Putten,et al.  Entry of OpaA+ gonococci into HEp‐2 cells requires concerted action of glycosaminoglycans, fibronectin and integrin receptors , 1998, Molecular microbiology.

[161]  M. D. Freedman,et al.  Pharmacodynamics, Clinical Indications, and Adverse Effects of Heparin , 1992, Journal of clinical pharmacology.

[162]  I. Vlodavsky,et al.  Substrate Specificity of Heparanases from Human Hepatoma and Platelets* , 1998, The Journal of Biological Chemistry.

[163]  K. Nagaki,et al.  Inactivator of the First Component of Human Complement (CĪINA) , 1974 .

[164]  R. Mahley,et al.  Human apolipoprotein E: the Alzheimer's disease connection , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[165]  T. Yeatman,et al.  Expression of annexins on the surfaces of non-metastatic and metastatic human and rodent tumor cells , 2004, Clinical & Experimental Metastasis.

[166]  Jian Liu,et al.  Purification of Heparan Sulfate D-Glucosaminyl 3-O-Sulfotransferase* , 1996, The Journal of Biological Chemistry.

[167]  A. Varki,et al.  Selectin ligands. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[168]  R. Langer,et al.  Expression in Escherichia coli, purification and characterization of heparinase I from Flavobacterium heparinum. , 1996, The Biochemical journal.

[169]  D. Spillmann,et al.  More to "heparin" than anticoagulation. , 1994, Thrombosis research.

[170]  H. Rauvala,et al.  Neurite Outgrowth in Brain Neurons Induced by Heparin-binding Growth-associated Molecule (HB-GAM) Depends on the Specific Interaction of HB-GAM with Heparan Sulfate at the Cell Surface (*) , 1996, The Journal of Biological Chemistry.

[171]  R. Mahley,et al.  Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. , 1986, The Journal of biological chemistry.

[172]  D. Arveiler,et al.  Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[173]  J. Weiler,et al.  Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. , 1994, Immunopharmacology.

[174]  A. Velázquez‐Campoy,et al.  Isothermal titration calorimetry , 1990 .

[175]  R. Sasisekharan,et al.  A comparative analysis of the primary sequences and characteristics of heparinases I, II, and III from Flavobacterium heparinum. , 1996, Biochemical and biophysical research communications.

[176]  T. McCaffrey,et al.  Transforming growth factor‐β1 is a heparin‐binding protein: Identification of putative heparin‐binding regions and isolation of heparins with varying affinity for TGF‐β1 , 1992 .

[177]  S. Soker,et al.  The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. , 1992, The Journal of biological chemistry.

[178]  K. Holme,et al.  Identification of structural features of heparin required for inhibition of herpes simplex virus type 1 binding. , 1995, Virology.

[179]  Å. Danielsson,et al.  Denaturation behavior of antithrombin in guanidinium chloride. Irreversibility of unfolding caused by aggregation. , 1985, Biochemistry.

[180]  S. Hoffman,et al.  Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjugates , 1992, The Journal of cell biology.

[181]  J. Weiler,et al.  Interaction of fibroblast growth factor-1 and related peptides with heparan sulfate and its oligosaccharides. , 1997, Archives of biochemistry and biophysics.

[182]  T. Lohman,et al.  Thermodynamics of ligand-nucleic acid interactions. , 1992, Methods in enzymology.

[183]  R. Kalaria,et al.  Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer's disease and other degenerative disorders , 1991, Neuropathology and applied neurobiology.

[184]  R. Belland,et al.  Adherence of pilus- Opa+ gonococci to epithelial cells in vitro involves heparan sulfate , 1995, The Journal of experimental medicine.

[185]  A. Varki,et al.  Endothelial Heparan Sulfate Proteoglycans That Bind to L-Selectin Have Glucosamine Residues with Unsubstituted Amino Groups (*) , 1995, The Journal of Biological Chemistry.

[186]  D. Stuart,et al.  Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate , 1996, Journal of virology.

[187]  J. Huntington,et al.  Mechanism of heparin activation of antithrombin. Evidence for reactive center loop preinsertion with expulsion upon heparin binding. , 1996, Biochemistry.

[188]  W. Langdon,et al.  c-Cbl Is Transiently Tyrosine-phosphorylated, Ubiquitinated, and Membrane-targeted following CSF-1 Stimulation of Macrophages (*) , 1996, The Journal of Biological Chemistry.

[189]  G. Torri,et al.  Mono- and bidimensional 500 MHz 1H-NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: evidence for conformational peculiarity of the sulfated iduronate residue. , 1985, Biochemical and biophysical research communications.

[190]  T. Lohman,et al.  Ion effects on ligand-nucleic acid interactions. , 1976, Journal of molecular biology.

[191]  J. Benz,et al.  Annexins: from structure to function. , 1997, Biological chemistry.

[192]  R. Peters,et al.  Low-molecular Weight Heparins in Venous and Arterial Thrombotic Disease , 1999, Thrombosis and Haemostasis.

[193]  A. Delacourte,et al.  Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide , 1993, Brain Research.

[194]  E. Bennett,et al.  Cloning and Expression of a Proteoglycan UDP-Galactose:β-Xylose β1,4-Galactosyltransferase I , 1999, The Journal of Biological Chemistry.

[195]  Wayne A. Hendrickson,et al.  Structure of a heparin-linked biologically active dimer of fibroblast growth factor , 1998, Nature.

[196]  H. Halvorson,et al.  Quantitative characterization of the thrombin-heparin interaction. Discrimination between specific and nonspecific binding models. , 1991, The Journal of biological chemistry.

[197]  R. Linhardt,et al.  Order out of complexity--protein structures that interact with heparin. , 2001, Current opinion in structural biology.

[198]  Martin A. Garrett The LIGO Scientific Collaboration , 2010 .

[199]  M. Pantoliano,et al.  Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. , 1994, Biochemistry.

[200]  U. R. Desai,et al.  Interaction of heparin with synthetic antithrombin III peptide analogues. , 1994, The Biochemical journal.

[201]  J. Turnbull,et al.  Patterns of sulphation in heparan sulphate: polymorphism based on a common structural theme. , 1992, The International journal of biochemistry.

[202]  L. Callahan,et al.  Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions , 1991, Journal of virology.

[203]  C. Power,et al.  Glycosaminoglycans mediate cell surface oligomerization of chemokines. , 1997, Biochemistry.

[204]  M. Sobel,et al.  Localization and characterization of a heparin binding domain peptide of human von Willebrand factor. , 1992, The Journal of biological chemistry.

[205]  M. Petitou,et al.  Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. , 1983, Biochemical and biophysical research communications.

[206]  J. Sodroski,et al.  Functional association of cyclophilin A with HIV-1 virions , 1994, Nature.

[207]  I. Björk,et al.  Decreased binding of heparin to antithrombin following the interaction between antithrombin and thrombin. , 1977, Thrombosis research.

[208]  J. V. van Putten,et al.  Sulfated Polysaccharide-Directed Recruitment of Mammalian Host Proteins: a Novel Strategy in Microbial Pathogenesis , 1999, Infection and Immunity.

[209]  J. Hopwood,et al.  Anticoagulant activity of heparin: Separation of high‐activity and low‐activity heparin species by affinity chromatography on immobilized antithrombin , 1976, FEBS letters.

[210]  G. S. Manning On the application of polyelectrolyte “limiting laws” to the helix‐coil transition of DNA. I. Excess univalent cations , 1972, Biopolymers.

[211]  R. Linhardt,et al.  NMR solution conformation of heparin-derived hexasaccharide. , 1996, The Biochemical journal.

[212]  U. R. Desai,et al.  Substrate specificity of the heparin lyases from Flavobacterium heparinum. , 1993, Archives of biochemistry and biophysics.

[213]  J. Esko,et al.  Turnover of Heparan Sulfate Depends on 2-O-Sulfation of Uronic Acids* , 1997, The Journal of Biological Chemistry.

[214]  J. Platt,et al.  Heparanase, a potential regulator of cell-matrix interactions. , 2000, Trends in biochemical sciences.

[215]  R. Eisenberg,et al.  A Novel Role for 3-O-Sulfated Heparan Sulfate in Herpes Simplex Virus 1 Entry , 1999, Cell.

[216]  M. Nugent,et al.  Potentiation and inhibition of bFGF binding by heparin: a model for regulation of cellular response. , 2000, Biochemistry.

[217]  I. Turko,et al.  Lysine-heparin interactions in antithrombin. Properties of K125M and K290M,K294M,K297M variants. , 1994, Biochemistry.

[218]  E. Goldsmith,et al.  Serpins: the uncut version. , 1994, Structure.

[219]  I. Björk,et al.  The role of Arg46 and Arg47 of antithrombin in heparin binding. , 1999, Biochemistry.

[220]  M. Giacca,et al.  Interaction of HIV-1 Tat Protein with Heparin , 1997, The Journal of Biological Chemistry.

[221]  W. Hendrickson,et al.  CD4: its structure, role in immune function and AIDS pathogenesis, and potential as a pharmacological target. , 1991, Current opinion in biotechnology.

[222]  H. Gewurz,et al.  Potentiation of C1-esterase inhibitor activity by heparin , 1976 .

[223]  Oliver J. C. Rick,et al.  Involvement of annexin V in the entry of influenza viruses and role of phospholipids in infection , 1996, FEBS letters.

[224]  J. Turnbull,et al.  Heparan sulphate proteoglycans: molecular organisation of membrane--associated species and an approach to polysaccharide sequence analysis. , 1992, Advances in experimental medicine and biology.

[225]  K. Haustein Pharmacokinetic and Pharmacodynamic Properties of Oral Anticoagulants, Especially Phenprocoumon , 1999, Seminars in thrombosis and hemostasis.

[226]  H. Ogawa,et al.  Glycosaminoglycan Binding Properties of Annexin IV, V, and VI* , 1998, The Journal of Biological Chemistry.

[227]  A. Linker,et al.  Structure of the antithrombin-binding site in heparin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[228]  R. Linhardt,et al.  Enzymatic modification of heparan sulfate on a biochip promotes its interaction with antithrombin III. , 2000, Biochemical and biophysical research communications.

[229]  C. Rider The potential for heparin and its derivatives in the therapy and prevention of HIV-1 infection , 1997, Glycoconjugate Journal.

[230]  A. Perlin,et al.  A proton magnetic resonance spectral study of heparin. : L-Iduronic acid residues in commercial heparins , 1968 .

[231]  V. Nussenzweig,et al.  Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes , 1993, The Journal of experimental medicine.

[232]  R. Linhardt,et al.  Glycosaminoglycans can influence fibroblast growth factor-2 mitogenicity without significant growth factor binding. , 1997, Biochemical and biophysical research communications.

[233]  R. Linhardt,et al.  Preparation and structural characterization of large heparin-derived oligosaccharides. , 1995, Glycobiology.

[234]  J. Esko,et al.  Repetitive Ser-Gly Sequences Enhance Heparan Sulfate Assembly in Proteoglycans (*) , 1995, The Journal of Biological Chemistry.

[235]  S. Straus,et al.  Specificity and affinity of binding of herpes simplex virus type 2 glycoprotein B to glycosaminoglycans , 1997, Journal of virology.

[236]  C. Power,et al.  Definition, function and pathophysiological significance of chemokine receptors. , 1998, Trends in pharmacological sciences.

[237]  T. Irimura,et al.  Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. , 1983, Science.

[238]  T. Lohman,et al.  Thermodynamics of charged oligopeptide-heparin interactions. , 1995, Biochemistry.

[239]  J. Weiler,et al.  Pattern and spacing of basic amino acids in heparin binding sites. , 1997, Archives of biochemistry and biophysics.

[240]  J. Abrahams,et al.  The anticoagulant activation of antithrombin by heparin. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[241]  C. Rider,et al.  Heparin specifically inhibits binding of V3 loop antibodies to HIV‐1 gp120, an effect potentiated by CD4 binding , 1994, AIDS.

[242]  William C. Olson,et al.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.

[243]  D. Spillmann,et al.  Structural Requirement of Heparan Sulfate for Interaction with Herpes Simplex Virus Type 1 Virions and Isolated Glycoprotein C* , 1997, The Journal of Biological Chemistry.

[244]  K. Murthy,et al.  RETRACTED: Crystal Structure of a Complement Control Protein that Regulates Both Pathways of Complement Activation and Binds Heparan Sulfate Proteoglycans , 2001, Cell.

[245]  H. Engelberg Orally Ingested Heparin Is Absorbed in, Humans , 1995 .

[246]  R. Rosenberg,et al.  Correlation between structure and function of heparin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[247]  J. Weiler,et al.  Glycosaminoglycan‐protein interactions: definition of consensus sites in glycosaminoglycan binding proteins , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[248]  P. Gallay,et al.  Host cyclophilin A mediates HIV‐1 attachment to target cells via heparans , 1999, The EMBO journal.

[249]  U. R. Desai,et al.  Structure elucidation of a novel acidic tetrasaccharide and hexasaccharide derived from a chemically modified heparin. , 1993, Carbohydrate research.

[250]  N. Copeland,et al.  Multiple Isoforms of Heparan Sulfate d-Glucosaminyl 3-O-Sulfotransferase , 1999, The Journal of Biological Chemistry.

[251]  H. Kitagawa,et al.  Recent advances in the study of the biosynthesis and functions of sulfated glycosaminoglycans. , 2000, Current opinion in structural biology.

[252]  T. Irimura,et al.  Tumor metastasis-associated heparanase (heparan sulfate endoglycosidase) activity in human melanoma cells. , 1986, Cancer letters.

[253]  C. Best,et al.  Preparation of Heparin and Its Use in the First Clinical Cases , 1959, Circulation.

[254]  J. J. Schwartz,et al.  Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? , 1997, The Journal of clinical investigation.

[255]  M. Götte,et al.  Functions of cell surface heparan sulfate proteoglycans. , 1999, Annual review of biochemistry.

[256]  D. Spillmann,et al.  Defining the Interleukin-8-binding Domain of Heparan Sulfate* , 1998, The Journal of Biological Chemistry.

[257]  R. Mahley,et al.  Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. , 1999, Journal of lipid research.

[258]  P. Roepstorff,et al.  Ligand-binding sites in human serum amyloid P component. , 1996, European journal of biochemistry.

[259]  M. Salmivirta,et al.  Heparan sulfate : a piece of information , 2004 .

[260]  M. Giacca,et al.  Multiple Interactions of HIV-I Tat Protein with Size-defined Heparin Oligosaccharides* , 1999, The Journal of Biological Chemistry.

[261]  E. Recondo,et al.  The first component of the human complement system recognizes the active fraction of heparin. , 1997, Cellular and molecular biology.

[262]  G. Siest,et al.  Kinetics of apolipoprotein E isoforms‐binding to the major glycosaminoglycans of the extracellular matrix , 1999, FEBS letters.

[263]  M. Levine,et al.  Do Heparins Do More than Just Treat Thrombosis? The Influence of Heparins on Cancer Spread , 1999, Thrombosis and Haemostasis.

[264]  M. Nakajima,et al.  Human Heparanase , 1999, The Journal of Biological Chemistry.

[265]  J. Gluckman,et al.  Glycan and glycosaminoglycan binding properties of stromal cell-derived factor (SDF)-1alpha. , 2000, Glycobiology.

[266]  L. Bernier,et al.  Apolipoprotein E and atherosclerosis: insight from animal and human studies. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[267]  R. Linhardt,et al.  Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. , 1993, Blood.

[268]  M. Burdick,et al.  CXC chemokines in angiogenesis , 2000, Journal of leukocyte biology.

[269]  Benito Casu,et al.  Evidence for conformational equilibrium of the sulfated L-iduronate residue in heparin and in synthetic heparin mono- and oligo-saccharides: NMR and force-field studies , 1986 .

[270]  J. Esko,et al.  Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate , 1997, Nature Medicine.